ALJ Regional Holdings is a holding company. The company's segments are: Faneuil, Inc., which provides call center services, back-office operations, staffing services and toll collection services, focusing on the healthcare, utility, transportation, and toll revenue collection industries; Floors-N-More, LLC, which is a floor covering retailer, and a provider of multiple products for the commercial, retail and home builder markets; and Phoenix Color Corp., which is a manufacturer of book components, educational materials and related products producing components, illustrated books and commercial products using a spectrum of materials and decorative technologies.

Americold Realty Trust is a real estate investment trust. The company is an owner and operator of temperature-controlled warehouses. The company's segments include: warehouse, in which the company provides temperature-controlled warehouse storage and related handling and other warehouse services; third-party managed, in which the company manages warehouses on behalf of third parties and provides warehouse management services to several food retailers and manufacturers in customer-owned facilities, including some of its customers; and transportation, in which the company brokers and manages transportation of frozen and perishable food and other products for its customers.

Blue Apron provides recipes, ingredients, and cooking techniques to preparing meals to sharing photos and stories of culinary triumphs. The company also sells wine, which can be paired with its meals, and the company sells a curated selection of cooking tools, utensils, and pantry items. The company's products include: Meals, which provides a 2-Person Plan that serves two people, and a Family Plan that serves four people; Wine, which provides wine delivery service, including red and white wines (and roses, depending on the season), tasting notes, pairing tips, and the story behind each wine; and Market, which provides a selection of cooking tools, utensils, and pantry items.

Chembio Diagnostics and its subsidiaries develop, manufacture, and commercialize point-of-care diagnostic tests that are used to detect and diagnose diseases. The company's product commercialization and product development activities are focused on infectious disease testing and technology collaborations. In infectious disease, the company is commercializing tests for human immunodeficiency virus and Syphilis, Zika virus, and developing tests for malaria, dengue virus, chikungunya virus, ebola, lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi, individually or as part of fever panel tests.

Core-Mark Holding Company is a wholesale distributor to the convenience retail industry, providing sales, marketing, distribution and logistics services to customer in the U.S. and Canada. The company purchases a variety of brand name and private label products from suppliers and manufacturers. The company provides a variety of food/non-food products, including fast food, candy, snacks, groceries, fresh products, dairy, bread, beverages, other tobacco products, alternative nicotine products, general merchandise and health and beauty care products. The company operates consolidation centers which buy products from its suppliers in bulk quantities and then redistribute the products to its other distribution centers.

Crimson Wine Group is engaged in the business of producing and selling wines. Through its wholly-owned subsidiaries, the company owns seven wineries: Pine Ridge Vineyards, Archery Summit, Chamisal Vineyards, Seghesio Family Vineyards, Double Canyon, Seven Hills Winery and Malene Wines. The company has two operating segments, Wholesale net sales and Direct to Consumer net sales. Wholesale net sales include all sales through a third party where prices are given at a wholesale rate, whereas Direct to Consumer net sales include retail sales in the tasting room, remote sites and on-site events, wine club net sales and other sales made directly to the consumer without the use of an intermediary.

Digital Turbine, through its subsidiaries, delivers end-to-end platform solution for mobile operators, application developers, device original equipment manufacturers (OEMs), and other third parties. The company's advertising business is comprised of Operator and OEM, an advertiser solution for carrier and OEM inventory comprised of services including Ignite?, a software platform with targeted media delivery and management capabilities; and Other recurring and lifecycle products, features, and services delivered on the Ignite platform. The company has launched Ignite with mobile operators and OEMs in North America, Latin America, Europe, Asia Pacific, India and Israel.

Evolus is a performance beauty company focused on delivering breakthrough products in the self-pay aesthetic market. The company's product, Jeuveau? (prabotulinumtoxinA-xvfs), is a 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. The company's primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance.

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. The company's product candidate is sacituzumab govitecan (IMMU-132), an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. The company also has other product candidates, which target solid tumors and hematologic malignancies in various stages of clinical and preclinical development, such as labetuzumab govitecan that binds the CEACAM5 antigen expressed on CRC and other solid cancers, and IMMU-140 for the treatment of hematologic malignancies.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

Lifeway Foods produces and markets probiotic-based products and natural foods. The company's primary product is kefir, a cultured dairy product that is a tart and tangy. The company's product are: drinkable kefir, which is sold in a variety of organic and non-organic sizes, flavors, and types, including low fat, non-fat, whole milk, protein, BioKefir (a 3.5 oz. kefir with additional probiotic cultures), and Kefir with oats; european-style soft cheeses; cream and other; ProBugs, which is a line of kefir products in drinkable, frozen, and freeze dried formats; other dairy, which includes Cupped Kefir and Icelandic Skyr, a line of strained kefir and yogurt products in resealable cups; and frozen kefir.

Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense through the development of potential medical counter-measures. The company's main drug development program is focused on delivering a long-term treatment for posttraumatic stress disorder. The company's primary product candidate, Tonmya, or TNX-102 SL, is a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration. TNX-102 SL is also being developed as a treatment for agitation in Alzheimer's disease.